Webinar presenters Melanie Pollan, PhD, Senior Director, Medical & Scientific Affairs, Siemens Healthineers Lab Diagnostics, and Alan H. B. Wu, PhD, Core Lab Co-Director Zuckerberg San Francisco General Hospital, and Christopher DeFilippi, MD, Director, Inova Biocore research laboratory and Vice-Chairman of Academic Affairs at Inova Schar Heart and Vascular in Northern Virginia discuss how the Atellica IM TnIH assay can be used to aid in offering rapid and accurate detection of AMI, helping lead to a faster diagnosis (versus contemporary Troponin assays); it can now also assist clinicians to identify future death and cardiovascular event risk based on the new prognosis indication for use. This assay is the first and only in the U.S. so far to include prognosis as part of the new, expanded intended use.
This on-demand webinar was originally broadcast on March 19, 2025.
What will you learn from this webinar?
• The clinical significance of High-Sensitivity Troponin testing to support acute and long-term cardiac care of patients.
• Real-life examples/case-studies and nuances in clinical outcomes based on patient history, risk-factors, clinical diagnosis protocol within institutions.
• New prognosis claim along with supporting data for different patient populations (with and without history of MACE, etc.) and how prognosis is utilized in healthcare systems.
• Learn from both a clinician and laboratorian perspective in the importance of coordinated long-term cardiac care management in patients presenting in the ED with suspected AMI.
• Ask questions of our distinguished presenters.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY.
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Siemens.